

Complete Summary

GUIDELINE TITLE

Guidelines for the use of antiretroviral agents in pediatric HIV infection.

BIBLIOGRAPHIC SOURCE(S)

Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Bethesda (MD): U.S. Department of Health and Human Services; 2008 Jul 29. 134 p. [355 references]

GUIDELINE STATUS

This is the current release of the guideline.

It updates a previous version: Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Bethesda (MD): U.S. Department of Health and Human Services; 2008 Feb 28. 134 p. [359 references]

The Working Group will revise these guidelines as new data regarding antiretroviral therapy for infected infants, children, and adolescents become available. Status information regarding this guideline is available from the [AIDSinfo Web site](#), telephone (800) 448-0440, fax (301) 519-6616; TTY (888) 480-3739.

**** REGULATORY ALERT ****

FDA WARNING/REGULATORY ALERT

Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

- [July 24, 2008, Ziagen \(abacavir sulfate\)](#): The U.S. Food and Drug Administration (FDA) has notified the maker of abacavir and abacavir-containing medications of the need to add information to the current BOXED WARNING about the recommendation to test all patients for the HLA-B*5701 allele before starting or restarting therapy with abacavir or abacavir-containing medications.
- [March 12, 2008, Prezista \(darunavir\)](#): The U.S. Food and Drug Administration (FDA) and Tibotec Therapeutics notified healthcare professionals of changes to the WARNINGS section of the prescribing information for Prezista (darunavir) tablets regarding the risk of hepatotoxicity, specifically, drug

induced hepatitis in patients receiving combination therapy with Prezista/ritonavir.

COMPLETE SUMMARY CONTENT

**** REGULATORY ALERT ****

SCOPE

METHODOLOGY - including Rating Scheme and Cost Analysis

RECOMMENDATIONS

EVIDENCE SUPPORTING THE RECOMMENDATIONS

BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

CONTRAINDICATIONS

QUALIFYING STATEMENTS

IMPLEMENTATION OF THE GUIDELINE

INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT

CATEGORIES

IDENTIFYING INFORMATION AND AVAILABILITY

DISCLAIMER

SCOPE

DISEASE/CONDITION(S)

- Human immunodeficiency virus (HIV) infection
- Acquired immunodeficiency syndrome (AIDS)

GUIDELINE CATEGORY

Diagnosis

Evaluation

Management

Treatment

CLINICAL SPECIALTY

Allergy and Immunology

Family Practice

Infectious Diseases

Internal Medicine

Pediatrics

INTENDED USERS

Advanced Practice Nurses

Allied Health Personnel

Health Care Providers

Health Plans

Hospitals

Nurses

Physician Assistants

Physicians
Public Health Departments

GUIDELINE OBJECTIVE(S)

To update the existing antiretroviral treatment guidelines for children and to provide guidelines for the antiretroviral treatment of human immunodeficiency virus (HIV)-infected infants, children, and adolescents similar to those for HIV-infected adults

TARGET POPULATION

Infants, children, and adolescents at risk for or infected with human immunodeficiency virus (HIV) in the United States

INTERVENTIONS AND PRACTICES CONSIDERED

Evaluation/Diagnosis

1. Identification of perinatal human immunodeficiency virus (HIV) exposure
2. Diagnosis of HIV in infants (HIV deoxyribonucleic acid [DNA] and ribonucleic acid [RNA] assays)
3. Laboratory monitoring (CD4 percentage or count, plasma HIV RNA)

Treatment/Management

1. Consideration of when to begin therapy in antiretroviral naïve children
2. Combination therapy with at least 3 drugs for antiretroviral-naïve children
 - Non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens (1 NNRTI + 2 nucleoside analogue reverse transcriptase inhibitor [NRTI] backbone)
 - Protease inhibitor (PI)-based regimens (1 or 2 PIs + 2 NRTI backbone)
 - Triple NRTI regimens (zidovudine + lamivudine + abacavir, recommended only in special circumstances)

Note: See the "Major Recommendations" and the original guideline document for detailed information about preferred and alternative regimens, as well as regimens to use only in special circumstances and those that are not recommended.

3. Monitoring of children on antiretroviral therapy for side effects, response to therapy, and adherence to regimen
4. Consideration of specific issues in antiretroviral therapy for HIV-infected adolescents
5. Strategies to maximize adherence to therapy
6. Management of the treatment-experienced child including:
 - Management of medication toxicity or intolerance
 - Assessment of antiretroviral treatment failure
 - Management of antiretroviral treatment failure
 - Changing antiretroviral regimen for treatment failure
 - Therapeutic drug monitoring
 - Discontinuation or interruption of therapy

7. Antiretroviral drug resistance testing
8. Coreceptor tropism assays

MAJOR OUTCOMES CONSIDERED

- Virologic response to antiretroviral therapy as measured by human immunodeficiency virus (HIV) ribonucleic acid (RNA) levels and immunologic response as measured by CD4 lymphocyte count/percent
- Disease progression based on virologic (HIV RNA load), immunologic (CD4+ cell count), or clinical (progressive neurodevelopmental deterioration, growth failure) parameters
- Toxicity of antiretroviral therapy
- Emergence of drug resistance
- Mortality rates
- Rates of opportunistic infections and other complications of HIV infection
- Quality of life

METHODOLOGY

METHODS USED TO COLLECT/SELECT EVIDENCE

Searches of Electronic Databases
Searches of Unpublished Data

DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE

Not stated

NUMBER OF SOURCE DOCUMENTS

Not stated

METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE

Expert Consensus (Committee)

RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE

Not applicable

METHODS USED TO ANALYZE THE EVIDENCE

Review
Review of Published Meta-Analyses

DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE

Not stated

METHODS USED TO FORMULATE THE RECOMMENDATIONS

Expert Consensus

DESCRIPTION OF METHODS USED TO FORMULATE THE RECOMMENDATIONS

In 1993, the Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children, composed of specialists caring for human immunodeficiency virus (HIV)-infected infants, children, and adolescents, was convened by the François-Xavier Bagnoud Center (FXBC), University of Medicine and Dentistry of New Jersey (<http://www.fxbcenter.org>). Since 1998, the Working Group has held monthly conference calls to review new data. Proposed changes to the pediatric treatment guidelines are reviewed by the Working Group and incorporated as appropriate.

Concepts Considered in the Formulation of Pediatric Treatment Guidelines

The following concepts were considered in the formulation of these guidelines:

- Prenatal HIV testing and counseling should be the standard of care for all pregnant women in the United States. Identification of HIV-infected women before or during pregnancy is critical to providing optimal therapy for both infected women and their infants and for reduction of perinatal transmission. Access to prenatal care is essential for all pregnant women.
- Enrollment of pregnant HIV-infected women; their HIV-exposed newborns; and infected infants, children, and adolescents into clinical trials offers the best means of determining safe and effective therapies.*
- The pharmaceutical industry and the federal government should continue collaboration that assures that drug formulations suitable for administration to infants and children are available for all antiretroviral drugs produced.
- Although some information regarding the efficacy of antiretroviral drugs for children can be extrapolated from clinical trials involving adults, concurrent clinical trials for children are needed to determine the impact of the drug on specific manifestations of HIV infection in children, including growth, development, and neurologic disease. However, the absence of phase III efficacy trials addressing pediatric-specific manifestations of HIV infection does not preclude the use of any approved antiretroviral drug in children.
- Treatment of HIV infection in infants, children, and adolescents is rapidly evolving and becoming increasingly complex; therefore, wherever possible, their treatment should be managed by a specialist in pediatric and adolescent HIV infection. If this is not possible, such experts should be consulted.
- Effective management of the complex and diverse needs of HIV-infected infants, children, adolescents, and their families requires a multidisciplinary team approach that includes physicians, nurses, dentists, social workers, psychologists, nutritionists, outreach workers, and pharmacists.
- Health care providers considering antiretroviral regimens for infants, children, or adolescents should consider certain factors influencing adherence to therapy, including:
 - Availability and palatability of pediatric formulations
 - Impact of the medication schedule on quality of life, including number of medications, frequency of administration, ability to co-administer

- with other prescribed medications, and need to take with or without food
- Ability of the child's caregiver or the adolescent to administer complex drug regimens and availability of resources that might be effective in facilitating adherence
- Potential for drug interactions
- The choice of antiretroviral regimens should include consideration of factors that may limit future treatment options, such as the presence of or potential for the development of antiretroviral resistance. HIV resistance assays have proven useful in guiding initial therapy and in changing failing regimens, but expert clinical interpretation is required.
- Monitoring growth and development, short- and long-term drug toxicities, neurodevelopment, symptom management, and nutrition are all essential in the care of HIV-infected children, as they may significantly influence quality of life; these issues are addressed in Supplement II: Managing Complications of HIV Infection (see "Availability of Companion Documents" field).

*In areas where enrollment in clinical trials is possible, enrolling the child in available trials should be discussed with the caregivers of the child. Information about clinical trials for HIV-infected adults and children can be obtained from the AIDSinfo Web site (<http://aidsinfo.nih.gov/>) or by telephone at 1-800-448-0440.

Criteria Used for Recommendations of Recommended Regimens for Initial Therapy for Antiretroviral-Naïve Children

There are few randomized, phase III clinical trials of highly active anti-retroviral therapy (HAART) among pediatric patients that provide direct comparison of different treatment regimens; most pediatric drug data come from phase I/II safety and pharmacokinetic trials and non-randomized, open-label studies. The Working Group reviews both child and adult clinical trial data published in peer-reviewed journals, data prepared by manufacturers for U.S. Food and Drug Administration (FDA) review, and data presented in abstract format at major scientific meetings. Recommendations on the optimal initial therapy for children are continually being modified as new data become available, new therapies or drug formulations are developed, and late toxicities become recognized.

Criteria used by the Working Group for recommending specific drugs or regimens include:

- Data demonstrating durable viral suppression, immunologic improvement, and clinical improvement (when such data are available) with the regimen, preferably in children as well as adults
- The extent of pediatric experience with the particular drug or regimen
- Incidence and types of short- and long-term drug toxicity with the regimen, with special attention to toxicity reported in children
- Availability and palatability of formulations appropriate for pediatric use, including taste, ease of preparation (e.g., powders), volume of syrups, and pill size and number
- Dosing frequency and food and fluid requirements
- Potential for drug interactions

The most extensive clinical trial data on initial therapy regimens in adults and children are available for 3 types of regimens based on drug class: non-nucleoside

reverse transcriptase inhibitors (NNRTI)-based (2 nucleoside reverse transcriptase inhibitors [NRTIs] plus an NNRTI); protease inhibitor (PI)-based (2 NRTIs plus a PI); and NRTI-based (3 NRTI drugs). NNRTI- or PI-based regimens are preferred for initial therapy; decisions about which type of regimen to choose should be individualized based on patient requirements. Each class-based regimen has advantages and disadvantages, which are delineated in more detail in the original guideline document (see Tables 9 – 12 in the original guideline document).

RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS

Recommendations for drugs or drug combinations for use in treatment-naïve children are classified in one of several categories as follow:

- **Preferred:** Drugs or drug combinations are designated as preferred for use in treatment-naïve children when clinical trial data in children or, more often, in adults have demonstrated optimal efficacy and durability with acceptable toxicity and ease of use, and studies have been performed to demonstrate safety and surrogate marker efficacy in children; additional considerations are listed in the original guideline document.
- **Alternative:** Drugs or drug combinations are designated as alternatives for initial therapy when clinical trial data in children or adults show efficacy but there are disadvantages compared to preferred regimens in terms of more limited experience in children; the extent of antiviral efficacy or durability is less well defined in children or less than a preferred regimen in adults; there are specific toxicity concerns; or there are dosing, formulation, administration, or interaction issues for that drug or regimen.
- **Use in Special Circumstances:** Some drugs or drug combinations are recommended only for use in special circumstances, when preferred or alternative drugs cannot be used.
- **Not Recommended:** A list of drugs and drug combinations that are not recommended for initial therapy in children is shown in Table 8 in the original guideline document. These drugs and drug combinations are not recommended either because of inferior virologic response, potential serious safety concerns (including potentially overlapping toxicities), or pharmacologic antagonism.
- **Insufficient Data to Recommend:** There are a number of drugs and drug combinations that are approved for use in adults that do not have pharmacokinetic or safety data available in children, or for which such data are too limited to make a recommendation for use for initial therapy in children. Some of these drugs and drug combinations may be appropriate for consideration in the management of the treatment-experienced child (see Management of the Treatment-Experienced Child in the original guideline document).

COST ANALYSIS

A formal cost analysis was not performed and published cost analyses were not reviewed.

METHOD OF GUIDELINE VALIDATION

External Peer Review

DESCRIPTION OF METHOD OF GUIDELINE VALIDATION

All revisions are summarized and highlighted on the AIDSinfo Web site and posted for a public comment period, generally for 2 weeks, after which comments are reviewed by the Working Group prior to finalization.

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

Definitions for the classes of recommendations for drugs or drug combinations for use in treatment-naïve children ("Preferred," "Alternative," "Use in Special Circumstances," "Not Recommended," and "Insufficient Data to Recommend") are provided at the end of the Major Recommendations field.

Note from the National Guideline Clearinghouse (NGC): The Department of Health and Human Services updated the "Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection" on July 29, 2008. The following guidelines reflect the current recommendations.

Identification of Perinatal Human Immunodeficiency Virus (HIV) Exposure

Working Group Recommendations

- Universal counseling and voluntary human immunodeficiency virus (HIV) testing early in pregnancy, including opt-out testing, is recommended as standard of care for all pregnant women in the United States.
- Repeat HIV testing is recommended in the third trimester for women at high risk of HIV infection who have negative HIV antibody tests earlier in pregnancy.
- Rapid HIV antibody testing is recommended to screen women who are seen at labor and have undocumented HIV status to allow intrapartum antiretroviral prophylaxis to be initiated prior to delivery in women identified as HIV-infected.
- Women who have not been tested for HIV prior to or during labor should be offered rapid testing during the immediate postpartum period or their newborns should undergo rapid HIV antibody testing, with counseling and consent of the mother unless state law allows testing without consent. This allows initiation of antiretroviral prophylaxis soon after delivery for infants born to HIV-infected women, counseling of HIV-infected women not to breastfeed their infant, and linkage to HIV-related medical care and services for both mother and child.

Diagnosis of HIV Infection in Infants

Working Group Recommendations

- Infants under age 18 months require virologic assays that directly detect HIV

- to diagnose HIV infection, since antibody assays cannot be used due to the persistence of maternal HIV antibody in this age group.
- Virologic diagnostic testing in infants with known perinatal HIV exposure is recommended at age 14 to 21 days; 1 to 2 months; and 4 to 6 months. Some experts also perform virologic testing at birth.
 - Preferred virologic assays include HIV deoxyribonucleic acid polymerase chain reaction (DNA PCR) and HIV ribonucleic acid (RNA) assays.
 - Many experts confirm the absence of HIV infection in infants with negative virologic tests by performing an antibody test at age 12 to 18 months to document seroreversion to HIV antibody negative status.
 - In children 18 months and older, HIV antibody assays can be used for diagnosis.

Laboratory Monitoring of Pediatric HIV Infection

Working Group Recommendations

- In children under age 5 years, CD4 percentage is preferred for monitoring immune status because of age-related changes in absolute CD4 count in this age group.
- CD4 percentage or count should be measured at the time of diagnosis of HIV infection and at least every 3 to 4 months thereafter.
- Plasma HIV RNA should be measured to assess viral load at the time of diagnosis of HIV infection and at least every 3 to 4 months thereafter.
- More frequent CD4 cell and plasma HIV RNA monitoring may be considered in infants less than age 6 to 12 months; in children with suspected clinical, immunologic, or virologic deterioration; to confirm an abnormal value; or when initiating or changing therapy.
- The age of the child must be considered when interpreting the risk of disease progression based on CD4 percentage or count and plasma HIV RNA level.
- Optimally, the goal of antiretroviral therapy is to reduce plasma HIV RNA levels to below the limits of quantitation on ultrasensitive assays and to normalize immune status.

Treatment Recommendations

General Considerations

A number of factors need to be considered in making decisions about initiating and changing antiretroviral therapy in children, including:

- Severity of HIV disease and risk of disease progression, as determined by age, presence or history of HIV-related or acquired immune deficiency syndrome (AIDS)-defining illnesses (see pediatric clinical staging system for HIV, Table 1 in the original guideline document), level of CD4 cell immunosuppression, and magnitude of HIV plasma viremia
- Availability of appropriate (and palatable) drug formulations and pharmacokinetic information on appropriate dosing in the child's age group

- Potency, complexity (e.g., dosing frequency, food and fluid requirements), and potential short- and long-term adverse effects of the antiretroviral regimen
- Effect of initial regimen choice on later therapeutic options
- Presence of comorbidity that could affect drug choice, such as tuberculosis, hepatitis B or C virus infection, or chronic renal or liver disease
- Potential antiretroviral drug interactions with other prescribed, over-the-counter, or alternative medications taken by the child
- The ability of the caregiver and child to adhere to the regimen

The following recommendations provide general guidance for decisions related to treatment of HIV-infected children, and flexibility should be exercised according to a child's individual circumstances. Guidelines for treatment of HIV-infected children are evolving as new data from clinical trials become available. Although prospective, randomized, controlled clinical trials offer the best evidence for formulation of guidelines, most antiretroviral drugs are approved for use in pediatric patients based on efficacy data from clinical trials in adults, with supporting pharmacokinetic and safety data from phase I/II trials in children. Additionally, efficacy has been defined in most adult trials based on surrogate marker data, as opposed to clinical endpoints. For the development of these guidelines, the Working Group reviewed relevant clinical trials published in peer-reviewed journals or in abstract form, with attention to data from pediatric populations when available.

Goals of Antiretroviral Treatment

The goals of antiretroviral therapy for HIV-infected children include:

- Reducing HIV-related mortality and morbidity
- Restoring and preserving immune function
- Maximally and durably suppressing viral replication
- Minimizing drug-related toxicity
- Maintaining normal physical growth and neurocognitive development
- Improving quality of life

Strategies to achieve these goals require complex balancing of sometimes competing considerations.

Use and selection of combination antiretroviral therapy: At present, the treatment of choice for HIV-infected children is at least 3 drugs, which include at least 2 classes of antiretroviral drugs. The Working Group has recommended several preferred and alternative regimens (see Recommendations on Antiretroviral Regimens for Initial Therapy in the original guideline document). The most appropriate regimen for an individual child depends on multiple factors, including age of the child and availability of appropriate drug formulations; the potency, complexity, and toxicity of the regimen; the child and caregiver's ability to adhere to the regimen; the child's home situation; and the child's antiretroviral treatment history.

Drug sequencing and preservation of future treatment options: The choice of antiretroviral treatment regimens should include consideration of future treatment options, such as the presence of or potential for drug resistance. Multiple changes

in antiretroviral drug regimens can rapidly exhaust treatment options, and should be avoided unless required (e.g., severe toxicity or intolerance or significant clinical, immunologic, or virologic progression). Appropriate sequencing of drugs for use in initial and second-line therapy can preserve future treatment options and is another strategy to maximize long-term benefit from therapy. Currently, recommendations for initial therapy are to use 2 classes of drugs—2 nucleoside analogue reverse transcriptase inhibitors (NRTIs) combined with either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or protease inhibitor (PI)—thereby sparing 3 classes of drugs for later use.

Maximizing adherence: As discussed in the Adherence Assessment and Monitoring section of the original guideline document, lack of adherence to prescribed regimens can lead to subtherapeutic levels of antiretroviral medications, which enhances the risk of the development of drug resistance and likelihood of virologic failure. Participation by the caregivers and child in the decision-making process is crucial. Issues related to adherence to therapy should be fully assessed, discussed, and addressed with the child's caregiver and the child (when age-appropriate) before the decision to initiate therapy is made. Potential problems should be identified and resolved prior to starting therapy, even if this delays initiation of therapy. Additionally, frequent follow-up is important to provide assessment of virologic response to therapy, drug intolerance, viral resistance, and adherence. Finally, in patients who experience virologic failure, it is critical to fully assess adherence before making changes to the antiretroviral regimen.

When to Initiate Therapy in Antiretroviral-Naïve Children (see Table 6 in the original guideline document)

The choice whether to start therapy early, while an individual is still asymptomatic, versus delaying therapy until clinical or immunologic symptoms appear, continues to generate considerable controversy among HIV experts. Some experts favor starting aggressive therapy in the early stages of HIV infection in the hope that early antiretroviral intervention will control viral replication prior to the onset of rapid genetic mutation and evolution into multiple quasispecies. This could result in a lower viral set point, fewer mutant viral strains, and potentially less drug resistance. Early therapy would slow immune system destruction and preserve immune function, preventing clinical disease progression. On the other hand, delaying therapy until later in the course of HIV infection, when clinical or immunologic symptoms appear, may result in reduced evolution of drug-resistant virus due to a lack of drug selection pressure, greater adherence to the therapeutic regimen when the patient is symptomatic rather than asymptomatic, and reduced or delayed adverse effects of antiretroviral therapy.

Recommendations for when to initiate therapy have been more aggressive in children than adults because HIV infection is primarily transmitted from mother to child, thereby allowing identification of the timing of infection in children; HIV disease progression in children is more rapid than in adults; and laboratory parameters are less predictive of risk of disease progression in children, particularly for young infants. As discussed in the Laboratory Monitoring of Pediatric HIV Infection section in the original guideline document, CD4 count and HIV RNA values vary considerably by age in children, and both markers are poorly predictive of disease progression and mortality in children younger than 12 months. Hence, recommendations for when to start therapy differ by age of the

child. As discussed earlier, in the HIV Pediatric Prognostic Markers Collaborative Study (HPPMCS) meta-analysis, CD4 percentage and HIV RNA levels were both independently predictive of the risk of clinical progression or death, although CD4 percentage was a stronger predictor of risk than HIV RNA levels. Based on data showing that surrogate-marker based risk of progression varies considerably by age but that CD4 count-associated risk of progression in children age 5 years or older is similar to young adults, the Working Group has moved to recommendations for 3 age bands for initiation of treatment: infants under age 12 months, children age 1 to <5 years, and children and adolescents age ≥ 5 years.

Antiretroviral-Naïve HIV-Infected Infants Under Age 12 Months

Working Group Recommendations (see Table 6 in the original guideline document)

- Initiation of antiretroviral therapy is *recommended* for infants aged <12 months, regardless of clinical status, CD4 percentage, or viral load.
- Issues associated with adherence must be fully assessed and discussed with the HIV-infected infant's caregivers before therapy is initiated.

While there is agreement among pediatric HIV experts that infected infants with clinical symptoms of HIV disease or with evidence of immune compromise should be treated, there remains controversy regarding treatment of asymptomatic infants with normal immunologic status. However, recent data from a South African clinical trial (Children with HIV Early Antiretroviral Therapy [CHER] study) of initiation of highly active antiretroviral therapy (HAART) in asymptomatic perinatally-infected children with normal CD4 percentage (CD4 $>25\%$) prior to age 12 weeks compared to waiting to start HAART until the child meets clinical or immune criteria, demonstrated a 75% reduction in early mortality. Most of the deaths in the children in the delayed arm occurred in the first 6 months after study entry. Because the risk of rapid progression is so high in young infants and based on the data from the CHER study, the Working Group recommends initiation of therapy for all infants age <12 months regardless of clinical status, CD4 percentage or viral load (see Table 6 in the original guideline document). It is critical that issues associated with adherence are fully assessed and discussed with the HIV-infected infant's caregivers and addressed before therapy is initiated.

Refer to the original guideline document for a detailed discussion.

Antiretroviral-Naïve HIV-Infected Children Age 1 Year or Older

Working Group Recommendations (see Table 6 in the original guideline document)

- Initiation of antiretroviral therapy is *recommended* for children age ≥ 1 year with AIDS or significant symptoms (clinical category C or most clinical category B conditions), regardless of CD4 percentage/count or plasma HIV RNA level.
- Initiation of antiretroviral therapy is also *recommended* for children age ≥ 1 year who have met the age-related CD4 threshold for initiating treatment

- (CD4 <25% for children aged 1 to <5 years and <350 cells/mm³ for children ≥5 years), regardless of symptoms or plasma HIV RNA level.
- Initiation of antiretroviral therapy should be *considered* for children age ≥1 year who are asymptomatic or have mild symptoms (clinical category N and A or the following clinical category B conditions: single episode of serious bacterial infection or lymphoid interstitial pneumonitis) and have CD4 ≥25% for children aged 1 to <5 years or ≥350 cells/mm³ for children ≥5 years and have plasma HIV RNA ≥100,000 copies/mL.
 - Initiation of antiretroviral therapy may be *deferred* for children age ≥1 year who are asymptomatic or have mild symptoms *and* who have CD4 ≥25% for children aged 1 to <5 years and ≥350 cell/mm³ for children ≥5 years and have plasma HIV RNA <100,000 copies/mL.

Because the risk of disease progression slows in children age ≥1 year, the option of deferring treatment can be considered for older children. It is clear that children with clinical AIDS or significant symptoms (clinical category C or B; see Table 1 in the original guideline document) are at high risk of disease progression and death; treatment is recommended by the Working Group for all such children, regardless of immunologic or virologic status. However, children age ≥1 year with mild clinical symptoms (clinical category A) or who are asymptomatic (clinical category N) are at lower risk of disease progression than those with more severe clinical symptoms. It should also be noted that some clinical category B conditions—a single episode of serious bacterial infection or lymphoid interstitial pneumonitis—are less prognostic of the risk of disease progression, and consideration of CD4 count and viral load may be useful in determining the need for therapy in such children.

Based on data in the original guideline document, the Working Group has the following recommendations for treatment of children aged 1 to <5 years. Initiation of antiretroviral therapy is recommended for children aged 1 to <5 years who have AIDS or significant HIV-related symptoms (CDC clinical category C and clinical category B, except for the following category B conditions: single episode of serious bacterial infection or lymphoid interstitial pneumonitis [Table 1 in the original guideline document]), regardless of CD4 percentage/count or HIV RNA level. Additionally, treatment is recommended for children in this age group if they have a CD4 percentage <25%, regardless of clinical symptoms or HIV RNA level. Treatment may be considered for children who are asymptomatic or have mild symptoms (clinical category N and A, or clinical category B disease due to a single episode of serious bacterial infection or lymphoid interstitial pneumonitis [Table 1 in the original guideline document]) with CD4 percentage ≥25% if plasma HIV RNA is >100,000 copies/mL. Antiretroviral therapy may be deferred in asymptomatic children age 1 to <5 years who have CD4 ≥25% and who also have plasma HIV RNA levels <100,000 copies/mL.

For children who are age 5 years or older, initiation of antiretroviral therapy is recommended if they have AIDS or significant HIV-related symptoms (CDC clinical category C and clinical category B, except for the following category B conditions: single episode of serious bacterial infection or lymphoid interstitial pneumonitis [Table 1 in the original guideline document]), regardless of CD4 percentage/count or HIV RNA level. Additionally, treatment is recommended for children in this age group if they have CD4 <350 cells/mm³, regardless of clinical symptoms or HIV

RNA level. Treatment may be considered for children who are asymptomatic or have mild symptoms (clinical category N and A, or clinical category B disease due to a single episode of serious bacterial infection or lymphoid interstitial pneumonitis [Table 1 in the original guideline document]) with CD4 ≥ 350 cells/mm³ if HIV RNA is $>100,000$ copies/mL and the CD4 count is >350 cells/mm³. Antiretroviral therapy may be deferred for asymptomatic or mildly symptomatic children age ≥ 5 years who have CD4 ≥ 350 cells/mm³ and who also have plasma HIV RNA levels $<100,000$ copies/mL.

When therapy is deferred, the health care provider should closely monitor virologic, immunologic, and clinical status (see the Laboratory Monitoring of Pediatric HIV Infection section in the original guideline document). Factors to be considered in deciding when to initiate therapy in such children include:

- Increasing HIV RNA levels (e.g., HIV RNA levels approaching 100,000 copies/mL)
- Rapidly declining CD4 count or percentage to values approaching the age-related threshold for consideration of therapy
- Development of clinical symptoms
- The ability of caregiver and child to adhere to the prescribed regimen

What Drugs to Start: Initial Combination Therapy for Antiretroviral-Naïve Children (see Tables 8 through 11 in the original guideline document)

Working Group Recommendations

- Combination therapy with at least 3 drugs, including either a protease inhibitor or non-nucleoside reverse transcriptase inhibitor plus a dual nucleoside analogue reverse transcriptase inhibitor backbone, is recommended for initial treatment of HIV-infected children.
- The goal of therapy in treatment-naïve children is to reduce HIV RNA levels to below the level of detection (if possible, as determined using ultrasensitive assays) and to preserve immune function for as long as possible.
- Infants who are identified as HIV-infected during the first 6 weeks of life while receiving zidovudine chemoprophylaxis should have zidovudine discontinued and initiate treatment with combination therapy with at least 3 drugs (with drug choice based on results from antiretroviral drug resistance testing and treatment only initiated following assessment and counseling of the caregivers regarding adherence to therapy).
- Antiretroviral drug resistance testing is recommended prior to initiation of therapy in all treatment-naïve children.

Recommended Regimens for Initial Therapy of Antiretroviral-Naïve Children (see Table 7 and 8 in the original guideline document)

NNRTI-Based Regimens (1 NNRTI + 2 NRTI backbone)

Working Group Recommendations

- Preferred NNRTI:

- Efavirenz in combination with 2 NRTIs for children age ≥ 3 years
- Nevirapine in combination with 2 NRTIs for children age < 3 years or who require a liquid formulation
- Alternative NNRTI:
 - Nevirapine in combination with 2 NRTIs (for children age ≥ 3 years)

The Working Group does not recommend the following NNRTIs as initial therapy in children:

- Etravirine, due to lack of pediatric formulation and pediatric pharmacokinetic data, no efficacy or safety data in children, and lack of data in antiretroviral naïve patients

Nevirapine and efavirenz both have an approved pediatric indication. Nevirapine is available in a liquid formulation, while efavirenz is not, although a liquid formulation of efavirenz is under study. Advantages and disadvantages of different NNRTI drugs are delineated in Table 10 in the original guideline document. Use of NNRTIs as initial therapy preserves the PI class for future use, and less dyslipidemia and fat maldistribution have been reported with the NNRTI class than with the PI class. Additionally, there is a lower pill burden with these agents when compared to PI-based regimens for children taking solid formulations. The major disadvantage of the current NNRTI drugs is that a single viral mutation can confer drug resistance, and cross-resistance develops between nevirapine and efavirenz. Rare but serious and potentially life-threatening skin and hepatic toxicity can occur with all drugs in this class, but is most frequent with nevirapine, at least in HIV-infected adults.

Efavirenz, in combination with 2 NRTIs, is the preferred NNRTI for initial therapy of children age ≥ 3 years based on clinical trial experience in children and because higher rates of toxicity have been observed with nevirapine in clinical trials in adults. Results of studies comparing virologic response to nevirapine- versus efavirenz-based regimens in adults are conflicting, and no comparative studies have been done in children. Because nevirapine therapy is associated with the rare occurrence of significant hypersensitivity reactions, including Stevens-Johnson syndrome, and rare but potentially life-threatening hepatitis, nevirapine is recommended as an alternative NNRTI for initial treatment of antiretroviral-naïve children age ≥ 3 years. Nevirapine is the preferred NNRTI for initial therapy of children age < 3 years or for children who require a liquid formulation.

PI-Based Regimens (1 or 2 PIs + 2 NRTI backbone)

Working Group Recommendations

- Preferred PI
 - Lopinavir/ritonavir in combination with 2 NRTIs
- Alternative PI (listed alphabetically)
 - Atazanavir in combination with low dose ritonavir and 2 NRTIs (for children age ≥ 6 years)
 - Fosamprenavir in combination low dose ritonavir and 2 NRTIs (for children age ≥ 6 years)

- Nelfinavir and 2 NRTIs (for children age ≥ 2 years)
- Use in special circumstances:
 - Atazanavir unboosted (for treatment-naïve adolescents age ≥ 13 years and >39 kg who are unable to tolerate ritonavir) in combination with 2 NRTIs (must be boosted with ritonavir if used with tenofovir)
 - Fosamprenavir unboosted (for children age ≥ 2 years) in combination with 2 NRTIs
 - For post-pubertal adolescents who weigh enough to receive adult doses: saquinavir in combination with low-dose ritonavir and 2 NRTIs

The Working Group does not recommend the following PIs as initial therapy in children either because of insufficient data, data related to toxicity or potency, or inconvenient dosing:

- Boosted PIs (other than those listed above) or full dose dual PIs
- Unboosted atazanavir-containing regimens in children age <13 years and/or <39 kg
- Tipranavir-, and darunavir-containing regimens
- Atazanavir + indinavir (potential for additive hyperbilirubinemia)
- Unboosted saquinavir
- Indinavir

Nine PIs are currently approved for use, 6 of which are approved for use in children and have pediatric drug formulations. Advantages and disadvantages of different PIs are delineated in Table 11 in the original guideline document. Advantages of PI-based regimens include excellent virologic potency, high barrier for development of drug resistance (requires multiple mutations), and sparing of the NNRTI drug class. However, the drugs have potential for multiple drug interactions due to metabolism via hepatic enzymes, and may be associated with metabolic complications such as dyslipidemia, fat maldistribution, and insulin resistance. Factors to be considered in selecting a PI-based regimen for treatment-naïve children include virologic potency, dosing frequency, pill burden, food or fluid requirements, availability of palatable pediatric formulations, drug interaction profile, toxicity profile (particularly related to metabolic complications), and availability of data in children (see Table 11 in the original guideline document for advantages and disadvantages and [Supplement I: Pediatric Antiretroviral Drug Information](#) in the original guideline document for detailed pediatric information on each drug).

Ritonavir acts as a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) isoenzyme, thereby inhibiting the metabolism of other PIs, and has been used in low doses combined with another PI as a "pharmacokinetic booster," increasing drug exposure by prolonging the second drug's half-life. Boosted PI-based regimens are commonly used in treatment of adults, but adequate pediatric data are only available for co-formulated lopinavir/ritonavir in children over age 6 weeks and atazanavir and fosamprenavir with low-dose ritonavir in children age ≥ 6 years. The appropriate dosing of ritonavir-boosted PI regimens for other combinations is not known in children, and additional pharmacokinetic studies are necessary before more definitive dosing recommendations can be made and before such regimens can be recommended for initial therapy of treatment-naïve children. Additionally, the use of low-dose ritonavir increases the potential for

hyperlipidemia and drug-drug interactions. Saquinavir with low-dose ritonavir may be considered in the special circumstance of post-pubertal adolescents who weigh enough to receive standard adult doses of the drugs.

The Working Group recommends coformulated lopinavir/ritonavir as the preferred PI for the treatment-naïve child based on virologic potency in adult and pediatric studies, high barrier to development of drug resistance, excellent toxicity profile in adults and children, and availability of appropriate dosing information for children. However, data comparing the efficacy of lopinavir/ritonavir to other PIs are limited in adults and not available in children. Three PIs can be considered as alternative PIs for use in children: atazanavir in combination with low dose ritonavir for children age ≥ 6 years, fosamprenavir in combination with low dose ritonavir for children age ≥ 6 years, or nelfinavir for children age ≥ 2 years. Other PIs that can be considered in special circumstances when preferred and alternative drugs are not available or are not tolerated include fosamprenavir alone in children age ≥ 2 years, atazanavir alone in adolescents age ≥ 13 years and >39 kg, or for older adolescents, saquinavir in combination with low dose ritonavir as discussed above. While good virologic and immunologic responses have been observed with indinavir-based regimens in adults, there is no liquid formulation and there has been a high rate of hematuria, sterile leukocyturia, and nephrolithiasis reported in pediatric patients with this drug. The incidence of hematuria and nephrolithiasis with indinavir therapy may be higher in children than adults. Therefore, indinavir alone or with ritonavir boosting is not recommended as initial therapy. Additionally, newer PIs such as tipranavir and darunavir are not recommended for initial therapy at the present time due to limited data on use in treatment-naïve individuals, but may be considered for use in children with treatment failure.

Triple NRTI Regimens

Working Group Recommendations

- Use in special circumstances:
 - A 3 NRTI-based regimen consisting of zidovudine + lamivudine + abacavir should only be used in special circumstances when a preferred or alternative NNRTI-based or PI-based regimen cannot be used as first-line therapy in treatment-naïve children (e.g., due to significant drug interactions or adherence concerns).

The Working Group does not recommend the following triple NRTI regimens as initial therapy in children due to inferior virologic potency:

- Tenofovir + abacavir + lamivudine
- Tenofovir + didanosine + lamivudine

Triple NRTI regimens are attractive for use in HIV-infected pediatric patients as initial therapy because of the ease of administration, availability of palatable liquid formulations, demonstrated tolerance, and avoidance of many drug interactions. Because these triple NRTI regimens can be administered twice a day in children (adolescents who can receive adult doses can consider the triple combination of zidovudine/lamivudine/abacavir in a fixed-dose single tablet formulation

[Trizivir]), they may also facilitate adherence. Data on the efficacy of triple NRTI regimens for treatment of antiretroviral-naïve children are limited; in small observational studies, response rates of 47% to 50% have been reported. In adult trials, these regimens have shown less potent virologic activity when compared to NNRTI- or PI-based regimens. Based on the results of these clinical trials and the potentially life-threatening hypersensitivity syndrome associated with abacavir use, the Working Group recommends that a 3 NRTI-based regimen consisting of zidovudine + lamivudine + abacavir should only be used in special circumstances when a preferred or alternative NNRTI-based or PI-based regimen cannot be used as first-line therapy in treatment-naïve children (e.g., due to significant drug interactions or concerns related to adherence).

Selection of Dual NRTI Backbone as Part of Initial Combination Therapy

Working Group Recommendations

- Preferred 2 NRTI backbone combinations:
 - Abacavir + (lamivudine *or* emtricitabine)
 - HLA B*5701 genetic testing should be considered for HIV-infected children prior to initiating abacavir-based therapy, and abacavir should not be given to a child who tests positive for HLA B*5701
 - Didanosine + emtricitabine
 - Zidovudine + (lamivudine *or* emtricitabine)
 - For post-pubertal or Tanner Stage 4 adolescents: tenofovir + (lamivudine *or* emtricitabine)
- Alternative 2 NRTI backbone combinations:
 - Zidovudine + (abacavir *or* didanosine)
- Use in special circumstances:
 - Stavudine + (lamivudine *or* emtricitabine)

The Working Group does not recommend the following dual NRTI backbones for use in children:

- Tenofovir-containing dual NRTI combinations in children in Tanner Stages 1 to 3 due to lack of pediatric dosing data and formulation and concerns related to bone toxicity
- Zidovudine + stavudine due to virologic antagonism
- Lamivudine + emtricitabine due to similar resistance pattern and no additive benefit
- Stavudine + didanosine due to toxicity (although not recommended for initial therapy, may be considered for use in antiretroviral-experienced children who require a change in therapy)

Currently, 6 NRTIs (zidovudine, didanosine, lamivudine, stavudine, abacavir, and emtricitabine) are FDA-approved for use in children less than 13 years of age. Dual NRTI combinations form the "backbone" of HAART regimens for both adults and children. Dual NRTI combinations that have been studied in children include zidovudine in combination with abacavir, didanosine, or lamivudine; abacavir in combination with lamivudine, stavudine, or didanosine; and emtricitabine in

combination with stavudine or didanosine. Advantages and disadvantages of different dual NRTI backbone options are delineated in Table 9 in the original guideline document.

The preferred dual NRTI combinations for initial therapy in children consist of a primary NRTI (abacavir, didanosine, or zidovudine) combined with either lamivudine or emtricitabine. The most extensive experience in children is with zidovudine in combination with lamivudine. Selection of the lamivudine- (or emtricitabine-) associated M184V mutation has been associated with increased susceptibility to zidovudine or tenofovir. This combination has extensive data on safety in children and is generally well tolerated. The major toxicities are bone marrow suppression, manifested as macrocytic anemia and neutropenia. Minor toxicities include gastrointestinal toxicity and fatigue.

Both lamivudine and emtricitabine are well tolerated with few side effects. While there is less experience in children with emtricitabine than lamivudine, it is similar to lamivudine, and the Working Group felt it could be substituted for lamivudine as one component of a preferred dual regimen (i.e., emtricitabine in combination with abacavir, didanosine, or zidovudine). The advantages of emtricitabine are once daily administration, ability to be coadministered with didanosine, and its recent availability as an oral solution. Both lamivudine and emtricitabine select for the M184V resistance mutation, which is associated with high-level cross resistance between both drugs, a modest decrease in susceptibility to abacavir and didanosine, and improved susceptibility to zidovudine, stavudine, and tenofovir.

Abacavir in combination with lamivudine has been shown to be as or possibly more potent than zidovudine in combination with lamivudine in both children and adults, but has the potential for abacavir-associated life-threatening hypersensitivity reactions in a small proportion of patients. Abacavir hypersensitivity is more common in individuals with certain HLA genotypes, particularly HLA B*5701 (see [Supplement I: Pediatric Antiretroviral Drug Information](#) in the original guideline document); however the prevalence of HLA B*5701 is much lower in African American and Hispanic than Caucasian individuals in the United States (2% to 2.5% compared to 8%); the majority of HIV-infected children in the United States are of minority race/ethnicity. Pre-treatment screening for HLA B*5701 prior to initiation of abacavir treatment resulted in a significant reduction in the rate of abacavir hypersensitivity reaction in a study in HIV-infected adults. Genetic screening for HLA B*5701 should be considered for HIV-infected children prior to initiating abacavir-based therapy. If testing is done, abacavir should not be given to children who test positive for HLA B*5701.

Didanosine in combination with emtricitabine is also a preferred dual NRTI combination because of the potential for once daily dosing. In a study in 37 treatment-naïve children aged 3 to 21 years, long-term virologic suppression was achieved with a once daily regimen of didanosine, emtricitabine, and efavirenz; 72% of subjects maintained HIV RNA suppression to <50 copies/mL through 96 weeks of therapy. Prescribing information for didanosine recommends administration on an empty stomach. However, this is impractical for infants who feed frequently, and may decrease medication compliance in older children by increasing regimen complexity. A comparison of didanosine given with or without

food in children found that systemic exposure was similar, but with slower and more prolonged absorption with food. To improve compliance, some practitioners recommend administration without regard to timing of meals for young children. However, there are inadequate data to allow a strong recommendation at this time, and it is preferred that didanosine be administered under fasting conditions when possible.

Tenofovir has been studied in HIV-infected children in combination with other NRTIs and as an investigational oral sprinkle/granule formulation. Tenofovir in combination with lamivudine or emtricitabine is a preferred dual NRTI combination for use in adolescents in Tanner Stage 4 or who are post-puberty. The fixed-dose combinations of tenofovir + emtricitabine and tenofovir + emtricitabine + efavirenz are both administered as one pill once daily and may be particularly useful to improve adherence in older adolescents. In studies in adults, tenofovir when used with lamivudine or emtricitabine in combination with efavirenz had potent viral suppression for up to 3 years and was superior to zidovudine/lamivudine in viral efficacy. A tenofovir-based dual NRTI combination has not been studied head-to-head with another dual NRTI backbone in a PI-based regimen but 48-week virologic efficacy of tenofovir + emtricitabine in combination with lopinavir/ritonavir was similar to that seen in trials with other dual NRTI backbones in treatment-naïve adults. However, decreases in bone mineral density have been shown in both adults and children taking tenofovir for 48 weeks in some, although not all, studies. At this time there are insufficient data to recommend use of this drug for initial therapy in infected children in Tanner Stage 1–3, in whom the risk of bone toxicity may be greatest (see [Supplement I: Pediatric Antiretroviral Drug Information](#) in the original guideline document for more detailed pediatric information). Renal toxicity has been reported in children as well as adults receiving tenofovir; in one single-center study, the rate of beta-2-microglobulinemia was higher in children receiving tenofovir than children receiving other antiretroviral agents (12/44 compared to 2/48, respectively), although creatinine clearance did not differ between groups. Because of potential bone toxicity and renal toxicity, the drug may have greater utility for treatment of children in whom other antiretroviral drugs have failed than for initial therapy of treatment-naïve children. There are numerous drug-drug interactions with tenofovir and other antiretroviral drugs, including didanosine, lopinavir/ritonavir, atazanavir, and tipranavir, complicating appropriate dosing of this drug.

Alternative dual NRTI combinations include zidovudine in combination with abacavir or didanosine. There is considerable experience with use of these dual NRTI regimens in children. However, zidovudine + abacavir (as well as zidovudine + lamivudine) had lower rates of viral suppression and more toxicity leading to switching than did abacavir + lamivudine in one European pediatric study.

The dual NRTI combination of stavudine in combination with lamivudine or emtricitabine is recommended for use in special circumstances because stavudine is associated with a higher risk of lipoatrophy and hyperlactatemia than other NRTI drugs. For example, for children with anemia in whom there are concerns related to abacavir hypersensitivity and who are too young to receive tenofovir, stavudine may be preferred to zidovudine due to its lesser hematologic toxicity.

Certain dual NRTI drug combinations are not recommended. These include zidovudine + stavudine due to pharmacologic interactions that can result in potential virologic antagonism. The drug structure of emtricitabine is similar to lamivudine and the same single resistance mutation confers cross-resistance, so these drugs should not be used in combination. The dual NRTI combination of stavudine + didanosine is also not recommended for use as initial therapy. In small pediatric studies, stavudine + didanosine demonstrated virologic efficacy and was well tolerated. However, in studies in adults, stavudine + didanosine-based combination regimens were associated with greater rates of neurotoxicity, pancreatitis, hyperlactatemia and lactic acidosis, and lipodystrophy than therapies based on zidovudine + lamivudine; additionally, cases of fatal and non-fatal lactic acidosis with pancreatitis/hepatic steatosis have been reported in women receiving this combination during pregnancy.

Insufficient Data for Recommendation for Initial Therapy for Children

Working Group Recommendations

Because of insufficient data for use as initial therapy, the following regimens should not be offered to children for initial therapy:

- Low-dose ritonavir-boosted PI regimens, with exceptions of lopinavir/ritonavir, atazanavir/ritonavir in children age ≥ 6 years, fosamprenavir/ritonavir in children age ≥ 6 years, and low dose ritonavir in combination with saquinavir in post-pubertal adolescents who can receive adult doses
- Dual (full dose) PI regimens
- NRTI plus NNRTI plus PI
- Tenofovir-containing regimens in children in Tanner Stages 1 to 3
- Enfuvirtide (T-20)-containing regimens
- Unboosted atazanavir-containing regimens in children age <13 years and/or <39 kg
- Tipranavir-containing regimens
- Darunavir-containing regimens
- Maraviroc-containing regimens
- Raltegravir-containing regimens
- Etravirine-containing regimens

What Not to Use: Antiretroviral Drug Regimens That Should Not Be Offered at Any Time (see Table 8 in the original guideline document)

Working Group Recommendations

The following regimens should not be offered to children at any time:

- Monotherapy
- Two NRTIs alone
- Certain 2 NRTI combinations as part of HAART regimen
- Two NRTIs + unboosted saquinavir
- Atazanavir + indinavir

- Tenofovir + didanosine + (lamivudine *or* emtricitabine)
- Tenofovir + abacavir + (lamivudine *or* emtricitabine)

Monitoring of Children on Antiretroviral Therapy

Working Group Recommendations

- Children who start a new antiretroviral regimen should be evaluated in person or by a phone call within 1 to 2 weeks of starting medication to screen for clinical side effects and to assure that they are taking medication properly.
- Children should be seen within 4 to 8 weeks to assess for possible side effects and to evaluate initial response to therapy. More frequent evaluation may be needed following initiation or change in therapy to support adherence to the regimen.
- Subsequently, children should have a monitoring visit at least every 3 to 4 months to assess both efficacy and potential toxicity of their antiretroviral regimens.

Children who start a new antiretroviral regimen or who change to a new regimen should be followed to assess effectiveness, adherence, tolerability, and side effects of the regimen. Frequent patient visits and intensive follow-up during the initial months after a new antiretroviral regimen is started are necessary to support and educate the family. The first few weeks of antiretroviral therapy can be particularly difficult for children and their caregivers. They must adjust their schedules to allow for consistent and routine administration of medication doses. Children may also experience side effects of medications, and the child and caregiver need assistance in determining whether the effects are temporary and can be tolerated or whether they are more serious or long-term and necessitate a visit to the clinician. Thus, it is prudent for the clinician to assess the child within 1 to 2 weeks of initiating therapy, either in person or with a phone call, to assure proper administration of medications and to evaluate clinical concerns. Many clinicians will plan additional contact (in person or by telephone) with the child and caregivers during the first few weeks of therapy to support adherence.

Baseline laboratory assessments should be done prior to initiation of therapy; these include CD4 count/percentage and HIV RNA level; complete blood count and differential; serum chemistries (including electrolytes, blood urea nitrogen [BUN], creatinine, glucose, hepatic transaminases, calcium, and phosphorus); pancreatic enzyme evaluations (amylase, lipase) if therapy is being initiated with a drug with potential pancreatic toxicity, such as didanosine; and serum lipid evaluation (cholesterol, triglycerides). The child should be seen within 4 to 8 weeks after initiating or changing therapy to obtain a clinical history, with a focus on potential adverse effects and to assess adherence to medications; perform a physical examination; evaluate efficacy of therapy (measurement of CD4 count/percentage and HIV RNA levels); and to obtain a laboratory evaluation for toxicity. More frequent evaluation may be needed following a change in therapy to support adherence to the regimen. At a minimum, laboratory assessments should include a complete blood count and differential, serum chemistries, and assessment of renal and hepatic function. Assessment of initial virologic response to therapy is

important, as an initial decrease in HIV viral load in response to antiretroviral treatment should be observed after 4 to 8 weeks of therapy.

Subsequently, children taking antiretroviral medication should have assessments of adherence, toxicity, and efficacy at least every 3 to 4 months. Table 14 in the original guideline document provides one proposed monitoring schema, which will require adjustment based on the specific therapy the child is receiving. Assessments should include basic hematology, chemistry, CD4 count/percentage, and HIV viral load. Monitoring of drug toxicities should be tailored to the particular medications the child is taking; for example, periodic monitoring of pancreatic enzymes may be desirable in children receiving didanosine, or of serum glucose and lipids in patients receiving PIs. Children who develop symptoms of toxicity should have appropriate laboratory evaluations (e.g., evaluation of serum lactate in a child receiving NRTI drugs who develops symptoms suspect for lactic acidosis) performed more frequently until the toxicity resolves. For further details of adverse effects associated with particular antiretroviral medications, please see [Supplement III: Adverse Drug Effects](#) in the original guideline document.

Specific Issues in Antiretroviral Therapy for HIV-Infected Adolescents

Working Group Recommendations

- Antiretroviral therapy regimens must be individually tailored to the adolescent, as those with perinatal exposure generally have a very different clinical course and treatment history than those who acquired HIV during adolescence.
- Appropriate dosing of antiretroviral medications for adolescents is complex, not always predictable, and dependent upon multiple factors, including Tanner staging of puberty, body mass and chronologic age.
- Effective and appropriate contraceptive methods should be selected to reduce the likelihood of unintended pregnancy. Providers should be aware of potential interactions between antiretroviral drugs and hormonal contraceptives, which could lower contraceptive efficacy.
- Efavirenz should be avoided for the adolescent girl who desires to become pregnant or who does not use effective and consistent contraception. Efavirenz also should be avoided throughout the first trimester of pregnancy.
- Pediatric and adolescent care providers should work with older adolescent patients to prepare them for transition into adult care settings.

Adherence to Antiretroviral Therapy in HIV-Infected Children and Adolescents

Working Group Recommendations

- Strategies to maximize adherence should be discussed prior to initiation of antiretroviral therapy and again at the time of changing regimens.
- Adherence to therapy must be stressed at each visit, along with continued exploration of strategies to maintain and/or improve adherence.
- Multiple methods of determining adherence to antiretroviral therapy should be used simultaneously (e.g., quantitative self-report, pharmacy refill checks, pill

- counts).
- A non-judgmental attitude and trusting relationship will foster open communication and ease assessment of adherence.

Adherence Assessment and Monitoring

The process of adherence preparation and assessment should begin before therapy is initiated or changed, and a routine adherence assessment should be incorporated into every clinic visit. A comprehensive assessment should be instituted for all children in whom antiretroviral treatment initiation or change is considered. Evaluations should include nursing, social, and behavioral assessments of factors that may affect adherence by the child and family and can be used to identify individual needs for intervention. Adherence preparation should focus on establishing a dialogue and a partnership in medication management. Specific, open-ended questions should be used to elicit information about past experience as well as concerns and expectations about treatment. When assessing readiness and preparing to begin treatment, it is important to obtain explicit agreement with the treatment plan, including strategies to support adherence.

Adherence is difficult to assess accurately; different methods of assessment have been shown to yield different results, and each approach has limitations. Both caregivers and health care providers often overestimate adherence. Regular monitoring is key to early identification of problems and can reinforce the importance of taking medications as prescribed.

Use of multiple methods to assess adherence is recommended. Viral load response to a new regimen is often the most accurate indication of adherence, but it may be a less valuable measure in children with long treatment histories and multi-drug-resistant virus. Other measures include quantitative self-report of missed doses by caregivers and children or adolescents (focusing on recent missed doses during a 3-day or 1-week period), descriptions of the medication regimens, and reports of barriers to administration of medications. Targeted questions about stress, pill burden, and daily routine are recommended. Pharmacy refill checks and pill counts can identify adherence problems not evident from self-reports. Electronic monitoring devices, such as Medication Event Monitoring Systems (MEMS) caps, which record opening of medication bottles on a computer chip in the cap, have been shown to be useful tools to measure adherence in some settings. Home visits can play an important role in assessing adherence, and in some cases, suspected nonadherence is confirmed only when dramatic clinical responses to antiretroviral therapy occur during hospitalizations or in other supervised settings. Preliminary studies suggest that monitoring plasma concentrations of PIs, or therapeutic drug monitoring, may be a useful method to identify nonadherence.

It is important for clinicians to recognize that nonadherence is a common problem and that it can be difficult for patients to share information about missed doses or difficulties adhering to treatment. Furthermore, adherence can change over time. An adolescent who was able to strictly adhere to treatment upon initiation of a regimen may not be able to maintain complete adherence over time. A non-judgmental attitude and trusting relationship fosters open communication and

facilitates assessment. It is often helpful to ask both older children and caregivers about missed doses and problems. There can be significant discrepancies between parent and child reports. Therefore, clinical judgment is required to best interpret adherence information obtained from multiple sources.

See the original guideline document for strategies to improve and support adherence, including regimen-related strategies, child/family-related strategies, and health care provider-related strategies.

Management of the Treatment-Experienced Child

Overview: Considerations Related to Changing Antiretroviral Therapy

Working Group Recommendations

- Children receiving antiretroviral therapy should be evaluated at least every 3 to 4 months to assess the effectiveness of this therapy.
- Evaluation should include an assessment of adherence, drug tolerability, and pharmacokinetic issues (e.g., potential drug interactions); current HIV RNA level and CD4 cell percentage/count and change over time; and clinical status.
- Children who experience treatment failure should be managed in consultation with a pediatric HIV specialist.
- Not all instances of treatment failure require an immediate change in therapy; careful assessment is required to evaluate the etiology of the treatment failure and determine an appropriate management strategy.
- Frequent switching of drug regimens can severely limit a child's future treatment options and should be avoided unless necessary.

Although many children can remain on stable antiretroviral therapy for several years, at some point reassessment of a therapeutic regimen will become necessary. This section will discuss the definitions, causes, assessment, and management of antiretroviral treatment failure and specific issues to consider when changing a drug regimen. Treatment failure is defined as suboptimal response or a lack of sustained response to therapy. It is important to recognize that not all instances of treatment failure require an immediate change in antiretroviral therapy, and a careful assessment is required to evaluate the etiology of treatment failure and determine the appropriate management strategy.

The assessment and management of treatment failure is more complex for children who have been on several antiretroviral drug regimens. A change in antiretroviral therapy should take into consideration the child's prior treatment experience, presence of drug-resistant virus, current immunologic and clinical status, ability to adhere to a new regimen, and the number of treatment options available. The assessment of treatment response, approach to managing treatment failure, and goals of therapy differ based on these characteristics, and decisions regarding changing antiretroviral therapy should be individualized and made in consultation with a pediatric HIV specialist.

A change in antiretroviral therapy may be considered in a number of different situations, including:

- Suboptimal virologic response to therapy or a sustained increase in viral load
- Suboptimal immune response to therapy or immunologic deterioration
- Suboptimal clinical response to therapy or clinical disease progression
- Significant drug intolerance or toxicity
- Significant and unmodifiable adherence issues

See the original guideline document for a discussion of the definitions and causes of antiretroviral treatment failure and Table 15 in the original guideline document, which discusses considerations for changing antiretroviral therapy in HIV-infected children.

Management of Medication Toxicity or Intolerance

Working Group Recommendations

- If a child has severe or life-threatening toxicity, all components of the drug regimen should be stopped immediately. Once the symptoms of toxicity have resolved, antiretroviral therapy should be resumed with substitution of another antiretroviral drug for the responsible drug.
- Children with moderate medication toxicity should continue on antiretroviral therapy when possible while an assessment is done to identify and substitute for the offending agent.
- Children with mild toxicity can be treated symptomatically, and do not require drug discontinuation or change in drug therapy.
- When changing therapy because of toxicity or intolerance to a specific drug, changing a single drug in a multi-drug regimen is permissible; if possible, an agent with a different toxicity and side effect profile should be chosen.
- The toxicity and the medication thought to be responsible for it should be documented in the medical record and the caregiver and patient made aware of the drug-related toxicity to assist in making future medication choices if care is transferred.
- Dose reduction is not a recommended option in the setting of antiretroviral toxicity except in the instance when therapeutic drug monitoring has been performed and indicated a drug concentration above the normal therapeutic range.

Management strategies for drug intolerance include:

- Symptomatic treatment of mild to moderate transient side effects
- Change from one drug to another drug to which the patient's virus is sensitive within the same drug class, if necessary (e.g., change to stavudine for zidovudine-related anemia or to nevirapine for efavirenz-related central nervous system symptoms)
- Change drug classes, if necessary (e.g., from PI to an NNRTI or vice versa) and if the patient's virus is sensitive to a drug in that class
- Dose reduction only when drug levels have been determined to be excessive

Assessment of Antiretroviral Treatment Failure

Working Group Recommendations

- Assessment of the patient with treatment failure should include:
 - Evaluation of adherence to therapy, drug intolerance, and pharmacokinetic issues
 - Antiretroviral treatment history and results of prior resistance testing
 - Current HIV RNA level and CD4 cell percentage/count and change over time
 - History and physical exam to assess clinical status
 - Future antiretroviral therapy options available
- In managing treatment change due to treatment failure, distinction should be made between limited (1 or 2 prior regimens), intermediate, and extensive prior treatment exposure and drug resistance.
- For children with virologic failure, drug resistance testing should be performed while the child is still receiving the failing antiretroviral regimen or within 4 weeks after regimen discontinuation.

Subsequent Management of Antiretroviral Treatment Failure

Working Group Recommendations

- When deciding how to treat a child with treatment failure, a clinician should consider the likelihood of achieving durable suppression based on the prior treatment history, drug resistance, likelihood of adherence, and the future options available should durable suppression not be achieved.
- The ideal goal of treatment is to reestablish and maintain maximal viral suppression.
- When durable viral suppression is not possible, preservation of immune function, prevention of clinical disease progression, and preservation of future antiretroviral options are the primary goals.

After adherence, drug intolerance/toxicity, and drug pharmacokinetics are ruled out or determined to be the cause of treatment failure, the child should be assessed to determine whether a change in the antiretroviral regimen is necessary. This will depend on the urgency and likelihood of achieving durable viral suppression. The urgency of achieving viral suppression depends on the clinical and immunologic status and reserve of the child. The likelihood of achieving and maintaining viral suppression depends on whether there is limited, intermediate, or extensive prior antiretroviral therapy and drug resistance and on the expectation of continued adherence to the regimen by the child and caregiver.

See the original guideline document for a discussion of the relative importance and likelihood of viral suppression.

Changing an Antiretroviral Regimen for Treatment Failure

Working Group Recommendations

- Perform resistance testing while the patient is still taking the drug regimen or within 4 weeks after regimen discontinuation.
- Antiretroviral regimens should be chosen based on treatment history and drug-resistance testing, including past and current resistance test results.
- Ideally, use at least 2 fully active antiretroviral medications in the new regimen, using the past treatment history and resistance test results to determine which antiretroviral medications will demonstrate antiretroviral activity.
- Specialist advice is recommended to interpret resistance test results showing complex combinations of mutations and to make recommendations about future treatment options.

General Approach

If possible, change at least 2 drugs to new antiretroviral agents on the basis of resistance testing or use of a new drug class. A change in one drug or addition of a single drug to a failing regimen is suboptimal. Whenever possible, the new regimen should contain at least 3 medications, with combinations guided by the same decision process used to develop the initial regimen. The potential for cross-resistance between antiretroviral drugs should be considered. A drug may be "new" to the patient but have diminished antiviral potency due to the presence of drug mutations that confer cross-resistance within a drug class. In children who are changing therapy due to neurodevelopmental clinical failure, choice of a new treatment regimen should include consideration of antiretroviral attributes that will allow control of plasma viremia as well as the ability of the drug to penetrate the central nervous system, which may also be associated with improvement in neurologic complications of HIV.

A change to a new regimen, especially one containing PIs or NNRTIs, must include a discussion of treatment adherence issues by the clinician with the patient, when age-appropriate, and with the caregivers of the infected child. The clinician must recognize that certain medications are difficult to take in combination because of exacting and often conflicting requirements with respect to whether they can be taken with food and other antiretroviral drugs. Palatability, pill size, pill number, and dosing frequency are part of the considerations in choice of new regimen and should be discussed with the child, when appropriate, and with the child's caregivers.

When changing therapy because of disease progression in a patient with advanced disease, the patient's quality of life must be considered. The relative benefits (reduced viral fitness, continued clinical benefit despite resistance, etc.) and burdens of continued antiretroviral therapy should be discussed. Decisions to continue or discontinue antiretroviral therapy should be made collaboratively with patients, families, and clinicians and should be consistent with the patient's/family's stated values and goals for care. There may be clinical and immunologic benefit in continuing a "failing" regimen because of the decrease in viral fitness associated with continuing therapy despite multi-drug-resistant virus and increasing viral load.

The creation of an effective and sustainable therapeutic regimen may be limited by the availability of potent and/or tolerable therapeutic agents. When deciding whether to change therapy and the contents of a new regimen, the clinician should consider the potential availability and future use of newer therapeutic agents that may be in clinical development. Information concerning potential clinical trials can be found at <http://aidsinfo.nih.gov> or through discussions with a pediatric HIV expert.

Failure of Initial First-Line Therapy: Choice of Second-Line Therapy

Antiretroviral regimens should be chosen based on treatment history and drug resistance testing to optimize antiretroviral drug potency in the second regimen. A general strategy for regimen change is shown in the Table below:

Table. Treatment Options Following Failure of Initial Antiretroviral Regimen*	
Initial Regimen	Recommended Change
2 NRTIs + NNRTI	<ul style="list-style-type: none"> 2 NRTIs (based on resistance testing) + protease inhibitor
2 NRTIs + protease inhibitor (PI)	<ul style="list-style-type: none"> 2 NRTIs (based on resistance testing) + NNRTI 2 NRTIs (based on resistance testing) + alternative protease inhibitor (with low-dose ritonavir boosting if possible, based on resistance testing) NRTI(s) (based on resistance testing) + NNRTI + alternative protease inhibitor (with low-dose ritonavir boosting if possible, based on resistance testing)
3 nucleosides (recommended only in special circumstances)	<ul style="list-style-type: none"> 2 NRTIs (based on resistance testing) + NNRTI or protease inhibitor NRTI(s) (based on resistance testing) + NNRTI + protease inhibitor
Failed regimens including NRTI, NNRTI, PI (recommended only in special circumstances)	<ul style="list-style-type: none"> >1 NRTI (based on resistance testing) + a newer protease inhibitor (with low-dose ritonavir, based on resistance testing)

* Antiretroviral regimens should be chosen based on treatment history and drug resistance testing to optimize antiretroviral drug effectiveness in the second regimen. This is particularly important in selecting NRTI components of an NNRTI-based regimen where drug resistance to the NNRTI may occur rapidly if the virus is not sufficiently sensitive to the NRTIs.

Multiple Antiretroviral Regimen Failure

The Table below provides some strategies for management of the multi-treatment-experienced child with treatment failure.

Table. Novel Strategies to Consider for Treatment-Experienced Children with Few Available Active Treatment Options
<ul style="list-style-type: none"> • Use of enfuvirtide (T-20) as part of a multi-drug regimen. Enfuvirtide has been shown to be most effective when used with at least one other new drug as part of the regimen.
<ul style="list-style-type: none"> • Pharmacologic enhancement with ritonavir may increase drug concentrations of most protease inhibitors (except nelfinavir) and may overcome some degree of drug resistance; there are little data on appropriate dosing of boosted protease inhibitors in children, but possible to consider for older children for whom dosing information may be available.
<ul style="list-style-type: none"> • Therapeutic drug monitoring may be considered (see "Therapeutic Drug Monitoring" in the original guideline document).
<ul style="list-style-type: none"> • Retreating with prior medications may be useful, particularly if they were discontinued previously for toxicities that can now be better addressed. Reusing prior medications (even with documented drug resistance) may provide some degree of partial antiretroviral activity. Continued drug therapy and maintenance of drug-resistant virus may compromise drug fitness, but it is not known if this has clinical applicability.
<ul style="list-style-type: none"> • The use of empiric multi-drug regimens (including up to 3 PIs and/or 2 NNRTIs) has been advocated by some, but may be limited by complexity, poor tolerability, and unfavorable drug-drug interactions.
<ul style="list-style-type: none"> • New antiretroviral drugs (drugs in existing classes with activity against resistant virus, such as the new PIs darunavir or tipranavir [both of which should be given with low dose ritonavir boosting] or the new NNRTI, etravirine, or new drug classes, such as CCR5 antagonists or integrase inhibitors, with novel mechanisms of action) including those available in clinical trials or on expanded access. Optimally, a new active agent should be used with one or more other active agents in the regimen.

For a discussion of additional specific issues to consider, including sequencing/cross-resistance and new agents, see the original guideline document.

Therapeutic Drug Monitoring

Therapeutic drug monitoring (TDM) is the term used to describe the use of plasma drug concentration measurements as part of a strategy to optimize drug dosing to minimize toxicity and maximize treatment benefit. TDM has been recommended for use in antiretroviral treatment because:

- There is high interpatient variability in antiretroviral exposure (plasma drug concentrations) using standard recommended doses
- Low drug exposure can lead to suboptimal virologic response to therapy
- High plasma concentrations can be associated with increased risk of drug toxicity

See Table 18 in the original guideline document for suggested minimum target trough concentrations for persons with wild-type HIV.

Discontinuation or Interruption of Therapy

Discontinuation of antiretroviral therapy may be indicated in some situations, including serious treatment-related toxicity, acute illnesses or planned surgeries that preclude oral intake, lack of available medication, or patient or parent request. While these events are usually unplanned, purposeful discontinuation of therapy has been widely used in the adult population to reduce toxicity, costs, and drug-related failure associated with antiretroviral therapy. At this time, there are minimal data in infants, children, and adolescents about planned structured treatment interruptions (STIs). Thus, STI should not be attempted in children or adults outside of a clinical trial setting. The discussion in the original guideline document provides general guidance for the interruption of antiretroviral therapy and the risks and benefits in specific situations, including short-term therapy interruption and long-term structured treatment interruptions.

Antiretroviral Drug Resistance Testing

Working Group Recommendations

- Antiretroviral drug resistance testing is recommended prior to initiation of therapy in all treatment-naïve children.
- Antiretroviral drug resistance testing is recommended prior to changing therapy for treatment failure.
- Resistance assays should be obtained when patients have a viral load of greater than 1,000 copies/mL and are still on the failing regimen or within 4 weeks of discontinuation of the regimen.
- The presence of viral resistance to a particular drug suggests the drug is unlikely to suppress viral replication.
- The absence of resistance to a drug does not ensure that its use will be successful, particularly if it shares cross-resistance with drugs previously used. Thus, the history of past use of antiretroviral agents as well as resistance testing is important in making decisions regarding the choice of new agents for patients with virologic failure.
- Consultation with a specialist in pediatric HIV infection is recommended for interpretation of resistance assays when considering starting or changing an antiretroviral regimen in a pediatric patient.

Coreceptor Tropism Assays

Working Group Recommendations

- Coreceptor tropism assays should be used whenever the use of a CCR5 antagonist is being considered.
- Coreceptor tropism assays might also be considered for patients who have virologic failure on CCR5-inhibitor-containing therapy.

Managing Complications of HIV Infection

The Pediatric Antiretroviral Treatment Guidelines includes the supplements [Managing Complications of HIV Infection](#) and [Adverse Drug Effects](#). These supplements contain guidelines on two important issues in pediatric HIV infection—nutrition and pain management—as well as separate sections on specific adverse drug effects, including lactic acidosis, hepatic toxicity, fat maldistribution and body habitus changes, hyperlipidemia, hyperglycemia, osteopenia, hematological complications, and hypersensitivity reactions and skin rashes. The United States Public Health Service (USPHS), HIV Medicine Association of the Infectious Diseases Society of America (IDSA), and Pediatric Infectious Disease Society jointly developed and published guidelines for the prevention and treatment of opportunistic infection in HIV-exposed and infected children, as well as adults. These guidelines are available online at the [AIDSinfo Web site](#). (See also the National Guideline Clearinghouse [NGC] summary [Treating Opportunistic Infections Among HIV-exposed and Infected Children](#)).

Definitions:

Guideline recommendations for drugs or drug combinations for use in treatment-naïve children are classified in one of several categories as follow:

- **Preferred:** Drugs or drug combinations are designated as preferred for use in treatment-naïve children when clinical trial data in children or, more often, in adults have demonstrated optimal efficacy and durability with acceptable toxicity and ease of use, and studies have been performed to demonstrate safety and surrogate marker efficacy in children; additional considerations are listed in the original guideline document.
- **Alternative:** Drugs or drug combinations are designated as alternatives for initial therapy when clinical trial data in children or adults show efficacy but there are disadvantages compared to preferred regimens in terms of more limited experience in children; the extent of antiviral efficacy or durability is less well defined in children or less than a preferred regimen in adults; there are specific toxicity concerns; or there are dosing, formulation, administration, or interaction issues for that drug or regimen.
- **Use in Special Circumstances:** Some drugs or drug combinations are recommended only for use in special circumstances, when preferred or alternative drugs cannot be used.
- **Not Recommended:** A list of drugs and drug combinations that are not recommended for initial therapy in children is shown in Table 8 in the original guideline document. These drugs and drug combinations are not recommended either because of inferior virologic response, potential serious safety concerns (including potentially overlapping toxicities), or pharmacologic antagonism.

- **Insufficient Data to Recommend:** There are a number of drugs and drug combinations that are approved for use in adults that do not have pharmacokinetic or safety data available in children, or for which such data are too limited to make a recommendation for use for initial therapy in children. Some of these drugs and drug combinations may be appropriate for consideration in the management of the treatment-experienced child (see "Management of the Treatment-Experienced Child" in the original guideline document).

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

Although prospective, randomized, controlled clinical trials offer the best evidence for formulation of guidelines, most antiretroviral drugs are approved for use in pediatric patients based on efficacy data from clinical trials in adults, with supporting pharmacokinetic and safety data from phase I/II trials in children. Additionally, efficacy has been defined in most adult trials based on surrogate marker data, as opposed to clinical endpoints. For the development of these guidelines, the Working Group reviewed relevant clinical trials published in peer-review journals or in abstract form, with attention to data from pediatric populations when available.

Recommendations are based on published and unpublished data regarding the treatment of human immunodeficiency virus (HIV) infection in infants, children, and adults and, when no definitive data were available, the clinical experience of the Working Group members.

BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

POTENTIAL BENEFITS

The goals of antiretroviral therapy for human immunodeficiency virus (HIV)-infected children include:

- Reducing HIV-related mortality and morbidity
- Restoring and preserving immune function
- Maximally and durably suppressing viral replication
- Minimizing drug-related toxicity
- Maintaining normal physical growth and neurocognitive development
- Improving quality of life

POTENTIAL HARMS

- The possibility of toxicities such as lipodystrophy, dyslipidemia, glucose intolerance, osteopenia, and mitochondrial dysfunction with prolonged

therapy is a concern. These concerns are particularly relevant because life-long administration of therapy may be necessary. See Appendix A "Characteristics of Available Antiretroviral Drugs" in the original guideline document and the companion document "Supplement III: Adverse Drug Effects" for major toxicities and adverse events associated with the antiretroviral drugs.

- Resistance to antiretroviral drugs can develop rapidly (particularly in the setting of high viral replication, as observed in infected infants) when drug concentrations are sub-therapeutic, either because of inadequate dosing, poor absorption, or incomplete adherence.
- Even small lapses in adherence can lead to antiretroviral treatment failure.

CONTRAINDICATIONS

CONTRAINDICATIONS

Please refer to Appendix A "Characteristics of Available Antiretroviral Drugs" in the original guideline document and the companion document "Supplement III: Adverse Drug Effects" for a list of contraindicated medications.

QUALIFYING STATEMENTS

QUALIFYING STATEMENTS

- Use of antiretrovirals in pediatric patients is evolving rapidly. These guidelines are updated regularly to provide current information. The most recent information is available at the [AidsInfo Web site](#).
- The Working Group intends the guidelines to be flexible and not to supplant the clinical judgment of experienced health care providers.

IMPLEMENTATION OF THE GUIDELINE

DESCRIPTION OF IMPLEMENTATION STRATEGY

An implementation strategy was not provided.

IMPLEMENTATION TOOLS

Foreign Language Translations
Patient Resources
Personal Digital Assistant (PDA) Downloads
Pocket Guide/Reference Cards
Slide Presentation

For information about [availability](#), see the "Availability of Companion Documents" and "Patient Resources" fields below.

INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

IOM CARE NEED

Living with Illness
Staying Healthy

IOM DOMAIN

Effectiveness
Patient-centeredness

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Bethesda (MD): U.S. Department of Health and Human Services; 2008 Jul 29. 134 p. [355 references]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

1999 Apr (revised 2008 Jul 29)

GUIDELINE DEVELOPER(S)

Centers for Disease Control and Prevention - Federal Government Agency [U.S.]
Health Resources and Services Administration - Federal Government Agency [U.S.]
National Institutes of Health (U.S.) - Federal Government Agency [U.S.]
National Pediatric and Family HIV Resource Center - Private Nonprofit Organization

SOURCE(S) OF FUNDING

United States Government

GUIDELINE COMMITTEE

Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children convened by the National Resource Center at the Francois-Xavier Bagnoud Center, University of Medicine and Dentistry of New Jersey

(UMDNJ), the Health Resources and Services Administration (HRSA), and the National Institutes of Health (NIH)

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Co-Chairs of the Working Group: Peter Havens, MD, Medical College of Wisconsin, Children's Hospital of Wisconsin, Milwaukee, WI; Russell Van Dyke, MD, Tulane University School of Medicine, New Orleans, LA; Geoffrey Weinberg, MD, University of Rochester School of Medicine, Rochester, NY

Members of the Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children: Elaine Abrams, MD (Harlem Hospital Center, New York, NY); Carolyn Burr, RN, EdD (Francois-Xavier Bagnoud Center, UMDNJ, Newark, NJ); Edmund Capparelli, MD (University of California--San Diego, La Jolla, CA); Diana Clarke, PharmD (Boston Medical Center, Boston, MA); Ken Dominguez, MD (Centers for Disease Control and Prevention, Atlanta, GA); Brian Feit (Health Resources and Services Administration, Rockville, MD); Patricia Flynn, MD (St. Jude's Medical Center, Memphis, TN); Marc Foca, MD (Columbia University College of Physicians and Surgeons, New York, NY); Edward Handelsman, MD (NIH, Bethesda, MD); Peter Havens, MD (Medical College of Wisconsin, Children's Hospital of Wisconsin, Milwaukee, WI); Rohan Hazra, MD (NIH, Bethesda, MD); Nancy Hutton, MD (Johns Hopkins School of Medicine, Baltimore, MD); Ebony Johnson, MHS (Children's National Medical Center, Washington, DC); Paul Krogstad, MD (University of California—Los Angeles, Los Angeles, CA); Linda Lewis, MD (FDA, Rockville, MD); James McAuley, MD, MPH (Rush University Medical Center, Chicago, IL); Mark Mirochnick, MD (Boston Medical Center, Boston, MA); Lynne M. Mofenson, MD (NIH, Bethesda, MD) (*Executive Secretary*); Paul Palumbo, MD (Dartmouth Medical School, Dartmouth, NH); Mary Paul, MD (Baylor College of Medicine, Houston, TX); Vicki B. Peters, MD (New York City Department of Health and Mental Hygiene, New York, NY); Richard Rutstein, MD (Children's Hospital of Philadelphia, Philadelphia, PA); Dorothy Shaw, BA (Birmingham, AL); George Siberry, MD, MPH (Johns Hopkins University); Deborah Storm, PhD (UMDNJ-New Jersey Medical School, Newark, NJ); Russell Van Dyke, MD (Tulane University School of Medicine, New Orleans, LA); Geoffrey Weinberg, MD (University of Rochester School of Medicine, Rochester, NY); Andrew Wiznia, MD (Jacobi Medical Center, Bronx, NY)

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Elaine Abrams

- None

Carolyn Burr

- None

Edmund Capparelli

- Arpida Pharmaceuticals (Consultant)
- Cadence Pharmaceuticals (Consultant)

- Elan Pharmaceuticals (Consultant)
- Glaxo Smith Kline (Consultant)
- InfraCare (Consultant)
- Mpex Pharmaceuticals (Consultant)
- Pfizer Inc. (Data and Safety Monitoring Board [DSMB] member [compensation <\$10,000 yearly])
- Wyeth Pharmaceuticals (Consultant)

Diana Clarke

- None

Kenneth Dominguez

- Antiretroviral Pregnancy Registry (administered by Kendle Interation, Co) (Advisory Board Member)

Brian Feit

- None

Pat Flynn

- MedImmune, Inc. (Clinical trial agreement)
- Tibotec (Clinical trial agreement)

Marc Foca

- Celestis (Honoraria)

Ed Handelsman

- None

Peter Havens

- None

Rohan Hazra

- None

Nancy Hutton

- None

Ebony Johnson

- None

Paul Krogstad

- None

Linda Lewis

- None

James McAuley

- Sanofi-Pasteur (Speakers' Bureau)

Mark Mirochnick

- GlaxoSmithKline (Clinical trial contract)

Lynne Mofenson

- None

Paul Palumbo

- None

Mary Paul

- None

Vicki Peters

- None

Linda Podhurst

- None

Richard Rutstein

- None

George Siberry

- None

Dorothy Shaw

- None

Deborah Storm

- Eli Lilly (Stockholder)
- Schering Plough (Stockholder)

Russell Van Dyke

- None

Geoffrey Weinberg

- Astellas Pharma US. (Grant recipient)
- Medimmune (Grant recipient; Advisory Board member)
- Merck & Co., Inc. (Speakers' Bureau)
- New York State Department of Health AIDS Institute (Consultant; Advisory Board member; honoraria)
- Sanofi Pasteur, Inc. (Speakers' Bureau)

Andrew Wiznia

- Abbott Pharmaceuticals (Honoraria)
- Gilead Sciences (Grant recipient; consultant)
- GlaxoSmithKline (Grant recipient)
- Merck & Co., Inc. (Grant recipient)
- Tibotec Pharmaceuticals Limited (Grant recipient; consultant)

GUIDELINE STATUS

This is the current release of the guideline.

It updates a previous version: Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Bethesda (MD): U.S. Department of Health and Human Services; 2008 Feb 28. 134 p. [359 references]

The Working Group will revise these guidelines as new data regarding antiretroviral therapy for infected infants, children, and adolescents become available. Status information regarding this guideline is available from the [AIDSinfo Web site](#), telephone (800) 448-0440, fax (301) 519-6616; TTY (888) 480-3739.

GUIDELINE AVAILABILITY

Electronic copies: Available from the [AIDSinfo Web site](#).

The guideline is also available for Palm OS or Pocket PC download from the [AIDSinfo Web site](#).

Print copies: Available from the Centers for Disease Control and Prevention, National Prevention Information Network (NPIN), P.O. Box 6003, Rockville, MD 20850. Telephone: (800) 458-5231, TTY (800)-243-7012 International number (301)-562-1098. Web site: <http://www.cdcnpin.org>. Requests for print copies can also be submitted via the [AIDSinfo Web site](#).

AVAILABILITY OF COMPANION DOCUMENTS

The following are available:

- Supplement I: pediatric antiretroviral drug information. Bethesda (MD): Department of Health and Human Services, Public Health Service (PHS), Centers for Disease Control and Prevention (CDC); 2001 Dec 14 (revised 2008 Jul 29). 65 p. Available in Portable Document Format (PDF) from the [AIDSinfo Web site](#). Also available for Palm OS or Pocket PC download from the [AIDSinfo Web site](#).
- Supplement II: managing complications of HIV infection in HIV-infected children on antiretroviral therapy. Bethesda (MD): Department of Health and Human Services, Public Health Service (PHS), Centers for Disease Control and Prevention (CDC); 2008 Feb 28. 18 p. Available in Portable Document Format (PDF) from the [AIDSinfo Web site](#). Also available for Palm OS or Pocket PC download from the [AIDSinfo Web site](#).
- Supplement III: adverse drug effects. Bethesda (MD): Department of Health and Human Services, Public Health Service (PHS), Centers for Disease Control and Prevention (CDC); 2008 Feb 28. 58 p. Available in Portable Document Format (PDF) from the [AIDSinfo Web site](#). Also available for Palm OS or Pocket PC download from the [AIDSinfo Web site](#).
- Antiretroviral Pocket Reference Cards. Antiretroviral agents pediatric edition. AIDS Educational and Training Center (AETC) 2008 Mar. Available from the [AETC Web site](#).
- Mofenson LM, Oleske J, Serchuck L, Van Dyke R, Wilfert C. Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. Clin Infect Dis. 2005 Feb 1;40 Suppl 1:S1-84. Available in Portable Document Format (PDF) from the [AIDSinfo Web site](#).

The following PowerPoint slide sets based on the "Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection" are also available:

- Guidelines for use of antiretroviral agents in pediatric HIV infection: comprehensive slide set. AIDS Education and Training Centers (AETC) National Resource Center. 2008 Jun . 90 slides. Available from the [AETC Web site](#).
- Pediatric antiretroviral guidelines: pain management. AIDS Education and Training Centers (AETC) National Resource Center. 2008 Mar 24. 26 slides. Available from the [AETC Web site](#).
- Pediatric antiretroviral guidelines: nutritional care. AIDS Education and Training Centers (AETC) National Resource Center. 2005 Mar 24. 20 slides. Available from the [AETC Web site](#).
- Pediatric antiretroviral guidelines: adverse drug effects. AIDS Education and Training Centers (AETC) National Resource Center. 2007 Sep 11. 48 slides. Available from the [AETC Web site](#).

The following tools are also available:

- AIDSinfo's Drug Database. Available in English and Spanish from the [AIDSinfo Web site](#). See the related QualityTool summary on the [Health Care Innovations Exchange Web site](#).
- AIDSinfo's HIV/AIDS Glossary, 4th ed. Available for PDA, in HTML format, and in Portable Document Format (English and Spanish) from the [AIDSinfo Web site](#). See the related QualityTool summary on the [Health Care Innovations Exchange Web site](#).
- A comprehensive Spanish-language Web site featuring information about HIV treatment and clinical trials is available at <http://aidsinfo.nih.gov/infoSIDA/>.

PATIENT RESOURCES

The following is available:

- HIV during pregnancy, labor and delivery, and after birth. Fact sheets. Rockville (MD): Department of Health and Human Services (DHHS); 2008 Jan. 9 p. Available in Portable Document Format (PDF) from the [AIDSinfo Web site](#).

Print copies: Available from the Centers for Disease Control and Prevention, National Prevention Information Network (NPIN), P.O. Box 6003, Rockville, MD 20850. Telephone: (800) 458-5231, TTY (800)-243-7012 International number (301)-562-1098. Web site: <http://www.cdcnpin.org>.

Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.

NGC STATUS

This summary was completed by ECRI on March 27, 1999. The original information was verified by the guideline developer on April 29, 1999. This summary was updated by ECRI on February 15, 2000, August 27, 2001, January 12, 2002, July 1, 2003, October 14, 2003, December 8, 2003, January 22, 2004, and December 1, 2004. This summary was updated on January 21, 2005, following the release of a public health advisory from the U.S. Food and Drug Administration regarding the use of nevirapine. This summary was updated on March 31, 2005, and November 8, 2005. This summary was updated by ECRI on July 3, 2006, following the U.S. Food and Drug Administration advisory on Aptivus (tipranavir). This NGC summary was updated by ECRI on November 3, 2006. This summary was updated by ECRI Institute on October 2, 2007, following the U.S. Food and Drug Administration advisory on Viracept (nelfinavir mesylate). This NGC summary was updated by ECRI Institute on March 14, 2008. This summary was updated by ECRI Institute on August 11, 2008.

COPYRIGHT STATEMENT

No copyright restrictions apply.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <http://www.guideline.gov/about/inclusion.aspx>.

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

© 1998-2008 National Guideline Clearinghouse

Date Modified: 9/15/2008

